ArticleMolecules (Basel, Switzerland)2026
Cannabidiol in Food and Food Supplements: Drug, Novel Food and Hazard Triangle.
Article in Molecules (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Regulation and Use of Cannabidiol in Croatia Compared with Selected European and International Models: From Consumer Products to Clinical Practice.Journal of clinical medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
The concept of the "cannabidiol (CBD) Hazard Triangle" reflects the unique position of CBD at the intersection of three overlapping dimensions: CBD as a substance associated with medicinal and pharmacological effects ("Drug"); CBD as a food ingredient subject to the EU Novel Food regulatory framework ("Novel Food"); and CBD as a potential source of food safety concerns ("Hazard"). This study investigates the growing presence of CBD-containing food products, their associated regulatory challenges, safety concerns, and market dynamics through an analysis of notifications reported in the EU Rapid Alert System for Food and Feed (RASFF), complemented by evidence from the scientific literature and authoritative regulatory sources. During the eight years (2018-2025), more than 400 CBD-related notifications were reported, predominantly involving food supplements (66.7%) and confectionery products, particularly gummies (12.6%). Significant discrepancies between the labelled and actual CBD content were frequently identified, along with unauthorized health claims implying therapeutic benefits. CBD-containing products were also found to contain other cannabinoids, most notably tetrahydrocannabinol (THC), which was reported in 26.7% of CBD-related hazard notifications. In several cases, THC concentrations exceeded legally permitted limits. Furthermore, these products are often marketed in forms that may promote casual or unintentional consumption, including by children. Overall, the widespread availability of CBD-containing food products raises important safety and regulatory concerns, particularly for vulnerable population groups. The CBD food market remains highly heterogeneous, characterized by inconsistent labelling practices, strong consumer demand, and increasing regulatory pressure. These findings underscore the need for clearer regulatory frameworks, improved market surveillance, and harmonized standards. Further research is essential to address unresolved issues related to product safety, quality, and market integrity.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.